These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28864947)

  • 1. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.
    Weberpals J; Jansen L; van Herk-Sukel MPP; Kuiper JG; Aarts MJ; Vissers PAJ; Brenner H
    Eur J Epidemiol; 2017 Nov; 32(11):1019-1031. PubMed ID: 28864947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study.
    Weberpals J; Jansen L; Haefeli WE; Hoffmeister M; Wolkewitz M; Herk-Sukel MPPV; Vissers PAJ; Brenner H
    Sci Rep; 2017 Jun; 7(1):2911. PubMed ID: 28588274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis.
    Weberpals J; Jansen L; Carr PR; Hoffmeister M; Brenner H
    Cancer Treat Rev; 2016 Jun; 47():1-11. PubMed ID: 27179912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: Results from a population-based study.
    Jansen L; Weberpals J; Kuiper JG; Vissers PAJ; Wolkewitz M; Hoffmeister M; Brenner H
    Int J Cancer; 2017 Jul; 141(1):62-71. PubMed ID: 28370155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients.
    Weberpals J; Jansen L; Silversmit G; Verbeeck J; van der Geest L; Vissers PA; Zadnik V; Brenner H
    Clin Epidemiol; 2018; 10():1109-1125. PubMed ID: 30214315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
    Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
    Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage-specific associations between beta blocker use and prognosis after colorectal cancer.
    Jansen L; Hoffmeister M; Arndt V; Chang-Claude J; Brenner H
    Cancer; 2014 Apr; 120(8):1178-86. PubMed ID: 24415516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods.
    Roche L; Danieli C; Belot A; Grosclaude P; Bouvier AM; Velten M; Iwaz J; Remontet L; Bossard N
    Int J Cancer; 2013 May; 132(10):2359-69. PubMed ID: 22961565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immortal time bias in pharmaco-epidemiology.
    Suissa S
    Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators.
    Mi X; Hammill BG; Curtis LH; Greiner MA; Setoguchi S
    J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S138-44. PubMed ID: 23849148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA
    Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.
    Holmes S; Griffith EJ; Musto G; Minuk GY
    Cancer Epidemiol; 2013 Dec; 37(6):881-5. PubMed ID: 24075077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
    Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between perioperative beta blocker use and cancer survival following surgical resection.
    Musselman RP; Bennett S; Li W; Mamdani M; Gomes T; van Walraven C; Boushey R; Al-Obeed O; Al-Omran M; Auer RC
    Eur J Surg Oncol; 2018 Aug; 44(8):1164-1169. PubMed ID: 29858097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink.
    O'Rorke MA; Murray LJ; Hughes CM; Cantwell MM; Cardwell CR
    Cancer Causes Control; 2015 Mar; 26(3):355-66. PubMed ID: 25534917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients.
    Hicks BM; Murray LJ; Hughes C; Cardwell CR
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):830-40. PubMed ID: 26017274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Socioeconomic variation in cancer survival in the southeastern Netherlands, 1980-1989.
    Schrijvers CT; Coebergh JW; van der Heijden LH; Mackenbach JP
    Cancer; 1995 Jun; 75(12):2946-53. PubMed ID: 7773946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
    Assayag J; Pollak MN; Azoulay L
    Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based survival from cancers having a poor prognosis in Mumbai (Bombay), India.
    Yeole BB; Kumar AV
    Asian Pac J Cancer Prev; 2004; 5(2):175-82. PubMed ID: 15244521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.